Altea Therapeutics And Teikoku Seiyaku Co. Ltd. Enter Into Agreement For A New Transdermal Therapy For Parkinson's Disease
ATLANTA--(BUSINESS WIRE)--Feb. 1, 2006--Altea Therapeutics announced today that it has entered an exclusive licensing agreement for Japan with Teikoku Seiyaku Co. Ltd. to develop and commercialize a new transdermal patch therapy that utilizes the Altea Therapeutics PassPort(TM) transdermal technology to deliver an active pharmaceutical ingredient for managing Parkinson's Disease.